{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-26-000053","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2026-08-10T11:49:17+00:00","discovered_at":"2026-08-10T11:50:11.381891+00:00","generated_at":"2026-08-10T11:50:20.196631+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AbCellera Phase 2 ABCL635 meets endpoints: 83% cut in hot flash frequency vs 33% placebo","bullets":["Phase 2 met primary endpoints: 8.8 mean reduction in daily moderate/severe hot flashes vs 3.5 placebo (p<0.001) at week 4 after single 600 mg dose","Frequency fell 83% vs 33% placebo (50% placebo-adjusted); severity down 58% vs 12% (46% adjusted, p<0.001)","92 postmenopausal women enrolled, 1:1 randomized; improvements in sleep and PGI-C also significant","No serious/severe AEs or discontinuations; common AEs: headache, fatigue, injection site reaction","Company plans Phase 3 validation; CMO Sarah Noonberg cites potential best-in-class single-dose relief"],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-26-000053","json":"https://secwatch.observer/filing/0001703057-26-000053.json","markdown":"https://secwatch.observer/filing/0001703057-26-000053.md","text":"https://secwatch.observer/filing/0001703057-26-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000053/0001703057-26-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000053/abcl-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:50:20.196631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}